This is a prospective, randomized, open-label clinical trial to evaluate the safety of administration of respiratory syncytial virus (RSV) preventive monoclonal antibody and other routine childhood vaccines given simultaneously at Visit 1, as compared to sequential administration of respiratory syncytial virus (RSV) preventive monoclonal antibody and other vaccines at separate visits (Visits 1 and 2).
Phase:
PHASE4
Details
Lead Sponsor:
Duke University
Collaborators:
Centers for Disease Control and Prevention Children's Hospital Medical Center, Cincinnati Columbia University Emory University Kaiser Permanente